Cargando…

Trends in Prices of Drugs Used to Treat Metastatic Non–Small Cell Lung Cancer in the US From 2015 to 2020

IMPORTANCE: Oncology drug prices are a determinant of health disparities in the US and worldwide. Several new therapeutic agents for non–small cell lung cancer (NSCLC) have become available on the US market over the past decade. Although increased competition typically produces lower prices, competi...

Descripción completa

Detalles Bibliográficos
Autores principales: Desai, Aakash, Scheckel, Caleb, Jensen, Chelsee J., Orme, Jacob, Williams, Colt, Shah, Nilay, Leventakos, Konstantinos, Adjei, Alex A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8790662/
https://www.ncbi.nlm.nih.gov/pubmed/35076701
http://dx.doi.org/10.1001/jamanetworkopen.2021.44923
_version_ 1784640066243526656
author Desai, Aakash
Scheckel, Caleb
Jensen, Chelsee J.
Orme, Jacob
Williams, Colt
Shah, Nilay
Leventakos, Konstantinos
Adjei, Alex A.
author_facet Desai, Aakash
Scheckel, Caleb
Jensen, Chelsee J.
Orme, Jacob
Williams, Colt
Shah, Nilay
Leventakos, Konstantinos
Adjei, Alex A.
author_sort Desai, Aakash
collection PubMed
description IMPORTANCE: Oncology drug prices are a determinant of health disparities in the US and worldwide. Several new therapeutic agents for non–small cell lung cancer (NSCLC) have become available on the US market over the past decade. Although increased competition typically produces lower prices, competition among brand-name oncology drugs has not resulted in lower prices. OBJECTIVE: To assess price changes in class-specific brand-name medications used to treat metastatic NSCLC in the US from 2015 to 2020. DESIGN, SETTING, AND PARTICIPANTS: This cross-sectional study, conducted from August 13, 2015, to August 13, 2020, used data from the Micromedex Red Book and Medi-Span Price Rx databases. The study sample was limited to 17 brand-name medications used to treat metastatic NSCLC that were available for purchase before January 1, 2019. MAIN OUTCOMES AND MEASURES: The main outcomes were trends over time in average wholesale prices and wholesale acquisition cost unit prices and the correlation in price among the multiple brand-name medications within each therapeutic class (immune checkpoint inhibitors, epidermal growth factor receptor inhibitors, anaplastic lymphoma kinase inhibitors, ROS1 inhibitors, BRAF inhibitors, and MEK inhibitors), measured using the Pearson correlation coefficient. The compounded annual growth rates of different medication costs were compared with the annual inflation rate and the consumer price index for prescription drugs. RESULTS: For all drug classes, the Pearson correlation coefficient approached 1.0, indicating an increase in drug list prices despite within-class drug competition. The median Pearson correlation coefficient values were 0.964 (range, 0.951-0.994) for immune checkpoint inhibitors, 0.898 (range, 0.665-0.950) for epidermal growth factor receptor inhibitors, 0.999 (range, 0.982-0.999) for anaplastic lymphoma kinase inhibitors, and 0.999 for BRAF and MEK inhibitors. The median compounded annual growth rates for most drug costs were higher than the annual inflation rate and consumer price index for prescription drugs: 1.81% (range, 1.29%-2.13%) for immune checkpoint inhibitors, 2.56% (range, 2.38%-5.26%) for epidermal growth factor receptor inhibitors, 2.46% (range, 1.75%-4.66%) for anaplastic lymphoma kinase and ROS1 inhibitors, and 3.06% (range, 0%-3.06%) for BRAF and MEK inhibitors. CONCLUSIONS AND RELEVANCE: In this cross-sectional study, prices of brand-name medications for treatment of NSCLC increased in the US from 2015 to 2020 without evidence of price competition, raising concern about the affordability of promising oncology drugs. These findings suggest that drug pricing reform is needed.
format Online
Article
Text
id pubmed-8790662
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher American Medical Association
record_format MEDLINE/PubMed
spelling pubmed-87906622022-02-07 Trends in Prices of Drugs Used to Treat Metastatic Non–Small Cell Lung Cancer in the US From 2015 to 2020 Desai, Aakash Scheckel, Caleb Jensen, Chelsee J. Orme, Jacob Williams, Colt Shah, Nilay Leventakos, Konstantinos Adjei, Alex A. JAMA Netw Open Original Investigation IMPORTANCE: Oncology drug prices are a determinant of health disparities in the US and worldwide. Several new therapeutic agents for non–small cell lung cancer (NSCLC) have become available on the US market over the past decade. Although increased competition typically produces lower prices, competition among brand-name oncology drugs has not resulted in lower prices. OBJECTIVE: To assess price changes in class-specific brand-name medications used to treat metastatic NSCLC in the US from 2015 to 2020. DESIGN, SETTING, AND PARTICIPANTS: This cross-sectional study, conducted from August 13, 2015, to August 13, 2020, used data from the Micromedex Red Book and Medi-Span Price Rx databases. The study sample was limited to 17 brand-name medications used to treat metastatic NSCLC that were available for purchase before January 1, 2019. MAIN OUTCOMES AND MEASURES: The main outcomes were trends over time in average wholesale prices and wholesale acquisition cost unit prices and the correlation in price among the multiple brand-name medications within each therapeutic class (immune checkpoint inhibitors, epidermal growth factor receptor inhibitors, anaplastic lymphoma kinase inhibitors, ROS1 inhibitors, BRAF inhibitors, and MEK inhibitors), measured using the Pearson correlation coefficient. The compounded annual growth rates of different medication costs were compared with the annual inflation rate and the consumer price index for prescription drugs. RESULTS: For all drug classes, the Pearson correlation coefficient approached 1.0, indicating an increase in drug list prices despite within-class drug competition. The median Pearson correlation coefficient values were 0.964 (range, 0.951-0.994) for immune checkpoint inhibitors, 0.898 (range, 0.665-0.950) for epidermal growth factor receptor inhibitors, 0.999 (range, 0.982-0.999) for anaplastic lymphoma kinase inhibitors, and 0.999 for BRAF and MEK inhibitors. The median compounded annual growth rates for most drug costs were higher than the annual inflation rate and consumer price index for prescription drugs: 1.81% (range, 1.29%-2.13%) for immune checkpoint inhibitors, 2.56% (range, 2.38%-5.26%) for epidermal growth factor receptor inhibitors, 2.46% (range, 1.75%-4.66%) for anaplastic lymphoma kinase and ROS1 inhibitors, and 3.06% (range, 0%-3.06%) for BRAF and MEK inhibitors. CONCLUSIONS AND RELEVANCE: In this cross-sectional study, prices of brand-name medications for treatment of NSCLC increased in the US from 2015 to 2020 without evidence of price competition, raising concern about the affordability of promising oncology drugs. These findings suggest that drug pricing reform is needed. American Medical Association 2022-01-25 /pmc/articles/PMC8790662/ /pubmed/35076701 http://dx.doi.org/10.1001/jamanetworkopen.2021.44923 Text en Copyright 2022 Desai A et al. JAMA Network Open. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the CC-BY License.
spellingShingle Original Investigation
Desai, Aakash
Scheckel, Caleb
Jensen, Chelsee J.
Orme, Jacob
Williams, Colt
Shah, Nilay
Leventakos, Konstantinos
Adjei, Alex A.
Trends in Prices of Drugs Used to Treat Metastatic Non–Small Cell Lung Cancer in the US From 2015 to 2020
title Trends in Prices of Drugs Used to Treat Metastatic Non–Small Cell Lung Cancer in the US From 2015 to 2020
title_full Trends in Prices of Drugs Used to Treat Metastatic Non–Small Cell Lung Cancer in the US From 2015 to 2020
title_fullStr Trends in Prices of Drugs Used to Treat Metastatic Non–Small Cell Lung Cancer in the US From 2015 to 2020
title_full_unstemmed Trends in Prices of Drugs Used to Treat Metastatic Non–Small Cell Lung Cancer in the US From 2015 to 2020
title_short Trends in Prices of Drugs Used to Treat Metastatic Non–Small Cell Lung Cancer in the US From 2015 to 2020
title_sort trends in prices of drugs used to treat metastatic non–small cell lung cancer in the us from 2015 to 2020
topic Original Investigation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8790662/
https://www.ncbi.nlm.nih.gov/pubmed/35076701
http://dx.doi.org/10.1001/jamanetworkopen.2021.44923
work_keys_str_mv AT desaiaakash trendsinpricesofdrugsusedtotreatmetastaticnonsmallcelllungcancerintheusfrom2015to2020
AT scheckelcaleb trendsinpricesofdrugsusedtotreatmetastaticnonsmallcelllungcancerintheusfrom2015to2020
AT jensenchelseej trendsinpricesofdrugsusedtotreatmetastaticnonsmallcelllungcancerintheusfrom2015to2020
AT ormejacob trendsinpricesofdrugsusedtotreatmetastaticnonsmallcelllungcancerintheusfrom2015to2020
AT williamscolt trendsinpricesofdrugsusedtotreatmetastaticnonsmallcelllungcancerintheusfrom2015to2020
AT shahnilay trendsinpricesofdrugsusedtotreatmetastaticnonsmallcelllungcancerintheusfrom2015to2020
AT leventakoskonstantinos trendsinpricesofdrugsusedtotreatmetastaticnonsmallcelllungcancerintheusfrom2015to2020
AT adjeialexa trendsinpricesofdrugsusedtotreatmetastaticnonsmallcelllungcancerintheusfrom2015to2020